Pharmacology of Vaccines and Sera

Introduction/Overview

Vaccines and sera constitute a distinctive therapeutic class that exploits the adaptive immune system to provide protection against infectious agents or to neutralize circulating toxins. Unlike conventional small‑molecule drugs, the pharmacological effects of these biologics are mediated through complex immunologic pathways rather than direct receptor binding in the traditional sense. Consequently, the study of vaccine and serum pharmacology requires an integrated understanding of immunology, molecular biology, and clinical pharmacology. The clinical relevance of this field is underscored by the pivotal role that vaccines play in public health, the expanding use of monoclonal and polyclonal antibody therapies, and the ongoing development of novel vaccine platforms such as mRNA and viral‑vector systems. Mastery of the pharmacology of these agents is essential for medical and pharmacy students who will be responsible for prescribing, administering, and monitoring such interventions in diverse patient populations.

Learning objectives

• Explain the classification and chemical nature of vaccine and serum preparations.
• Describe the principal mechanisms by which vaccines and sera elicit protective immunity.
• Outline the pharmacokinetic principles that govern the distribution and clearance of vaccine antigens and antibody products.
• Identify approved indications and off‑label uses for major vaccine and serum classes.
• Recognize common adverse effects, serious reactions, and drug interactions related to these biologics.
• Apply special patient‑centric considerations to the selection and administration of vaccines and sera.

Classification

Vaccines

Vaccines are conventionally classified according to the nature of the antigenic material and the method of antigen preparation. The major categories include:

• Live attenuated vaccines – contain weakened forms of the pathogen that are capable of limited replication.
• Inactivated (killed) vaccines – contain chemically or physically inactivated organisms or subunits.
• Subunit, recombinant, and conjugate vaccines – comprise purified proteins, polysaccharides, or protein‑polysaccharide conjugates that elicit specific immune responses.
• Toxoid vaccines – consist of detoxified exotoxins that induce neutralizing antibodies against the toxin.
• mRNA and viral‑vector vaccines – deliver nucleic acid or viral vectors encoding antigenic proteins, leading to in‑vivo antigen expression.
• DNA vaccines – plasmid DNA encoding antigens is introduced, prompting host cell synthesis of the antigenic protein.

In addition, adjuvants are often incorporated to enhance immunogenicity. Common adjuvants include aluminum salts (alum), oil emulsions, toll‑like receptor agonists, and saponin‑based formulations.

Sera

Sera, also referred to as antiserum or immune globulin preparations, are classified according to their source and specificity:

• Polyclonal sera – derived from the plasma of immunized donors and contain a heterogeneous mix of antibodies against multiple epitopes of the antigen.
• Monoclonal antibodies – produced by hybridoma technology or recombinant expression systems, offering high specificity for a single epitope.
• Human immunoglobulin preparations – pooled plasma products used for passive immunity against a range of pathogens.
• Targeted biologics – engineered antibodies designed to neutralize specific toxins or target cell surface molecules (e.g., anti‑toxin antibodies for botulism).

Mechanism of Action

Vaccines

The pharmacodynamic effect of vaccines is mediated through sequential activation of innate and adaptive immune responses. Initially, vaccine antigens are taken up by antigen‑presenting cells (APCs) such as dendritic cells, macrophages, or B cells. Antigen processing and loading onto major histocompatibility complex (MHC) molecules facilitate the presentation of peptides to T lymphocytes, thereby initiating T‑cell priming. Helper T cells (CD4⁺) release cytokines that support B‑cell proliferation, differentiation, and class switching, ultimately leading to the production of high‑affinity, antigen‑specific antibodies. Cytotoxic T cells (CD8⁺) are activated in the context of intracellular antigens, particularly relevant for live attenuated and viral‑vector vaccines. Memory B and T cells persist long after vaccination, providing rapid and robust responses upon subsequent exposure to the pathogen.

In the case of subunit or conjugate vaccines, the absence of whole pathogens necessitates the inclusion of adjuvants to compensate for lower immunogenicity. Aluminum salts, for instance, promote antigen depot formation and activate the inflammasome pathway, thereby enhancing antigen uptake and cytokine release. Oil‑in‑water emulsions such as MF59 stimulate neutrophil recruitment and local cytokine production, which augments APC activation. Toll‑like receptor (TLR) agonists directly engage innate pattern‑recognition receptors, leading to up‑regulation of co‑stimulatory molecules and a heightened adaptive response.

mRNA vaccines employ a different pharmacodynamic strategy: the mRNA, delivered within lipid nanoparticles, is translated by host ribosomes into the target antigenic protein. The synthesized protein is then processed and presented via MHC class I molecules, thereby eliciting both humoral and cellular immunity. This mechanism allows for rapid antigen expression without the need for viral replication, potentially reducing the risk of vaccine‑associated disease.

Sera (Antibody Preparations)

Passive immunization relies on the direct provision of functional antibodies that bind circulating antigens or toxins. The primary pharmacodynamic action occurs through antigen neutralization, whereby the antibody prevents the pathogen or toxin from interacting with host receptors. Additionally, antibody binding can initiate complement activation, leading to opsonization and lysis of the target organism or toxin. Antibody–antigen complexes may also engage Fcγ receptors on phagocytes, enhancing clearance via phagocytosis. In the context of monoclonal antibodies, the specificity for a single epitope can be exploited to neutralize toxins with high precision, as seen with botulinum antitoxin preparations.

Some antibody preparations are engineered for extended half‑life or altered effector functions. For example, Fc engineering techniques can increase binding affinity to neonatal Fc receptor (FcRn), thereby reducing catabolism and prolonging circulation time. Such modifications can improve the pharmacokinetic profile and therapeutic efficacy of sera products.

Pharmacokinetics

Absorption

Vaccine antigens are typically administered via intramuscular (IM), subcutaneous (SC), or intradermal (ID) routes. The rate and extent of antigen absorption depend on several factors, including the physicochemical properties of the antigen, the presence of adjuvants, and the injection site. Intramuscular injections generally provide more consistent systemic absorption compared to subcutaneous routes, owing to greater vascularity of muscle tissue. Intradermal delivery, while limiting the volume that can be administered, offers a high density of dendritic cells, potentially enhancing immunogenicity. For mRNA and viral‑vector vaccines, the lipid nanoparticles facilitate cellular uptake and endosomal escape, enabling efficient translation of the antigenic protein.

Passive antibody products are often administered intravenously (IV) or intramuscularly. IV administration yields immediate peak serum concentrations (C_max) and allows for precise dosing. SC and IM routes can result in slower absorption, with a prolonged time to reach C_max, which may be advantageous for maintaining therapeutic antibody levels over extended periods. The absorption rate constant (k_a) for immunoglobulin preparations is generally lower than that for small molecules, reflecting the larger molecular size and the reliance on lymphatic transport.

Distribution

Vaccine antigens are largely confined to the interstitial fluid at the injection site and the regional lymph nodes, where APCs capture the antigen. The distribution volume (V_d) for vaccine antigens is typically small, as the antigens are processed locally rather than disseminating widely. However, certain vaccine components, such as lipids in lipid‑nanoparticle formulations, may circulate systemically and accumulate in tissues with high lipid content.

Antibody products distribute extensively throughout the vascular and interstitial compartments. The apparent distribution volume for human IgG is approximately 4–5 L/m², reflecting its ability to traverse capillary walls via transcytosis mediated by FcRn. Tissue penetration is limited by molecular size, but FcRn expression in the endothelium facilitates transcytosis into tissues such as the liver, spleen, and bone marrow. The distribution kinetics of monoclonal antibodies can be further influenced by target‑mediated drug disposition (TMDD), where binding to high‑density antigens in tissues drives redistribution and elimination.

Metabolism

Vaccine antigens are metabolized primarily via proteolytic degradation by host proteases, resulting in peptide fragments that are presented to T cells. The metabolic pathway is largely enzymatic and does not involve hepatic cytochrome P450 enzymes. Consequently, vaccine antigens are unlikely to be involved in classic drug–drug interactions mediated through metabolic pathways.

Monoclonal and polyclonal antibodies undergo proteolytic catabolism in the reticuloendothelial system, predominantly within macrophages and hepatocytes. The rate of catabolism is governed by FcRn recycling; antibodies that bind FcRn at acidic pH are protected from lysosomal degradation and are recycled back to the circulation. Loss of FcRn binding, due to Fc engineering or disease states, typically accelerates antibody clearance and reduces half‑life (t_1/2).

Excretion

Vaccine antigens are cleared by phagocytic cells and hepatobiliary pathways, ultimately leading to excretion in feces or urine as degraded peptides. The elimination half‑life of vaccine antigens is generally short, ranging from minutes to hours, but the immunologic memory persists long after antigen clearance.

Immunoglobulin preparations are primarily eliminated by proteolytic catabolism. Only a fraction of the administered antibody is cleared per unit time; therefore, the terminal half‑life of IgG is typically 21–28 days. The elimination rate (k_el) is influenced by factors such as age, renal function, and the presence of antigens that may bind the antibody and promote clearance.

Half‑life and Dosing Considerations

Because vaccine antigens are short‑lived, dosing regimens are designed to achieve optimal immunogenicity rather than maintain steady‑state concentrations. Primary series vaccinations often require multiple doses spaced weeks apart, followed by booster doses at intervals determined by the durability of the immune response. For mRNA vaccines, the rapid translation and subsequent antigen expression may allow for fewer booster doses, although this remains an area of active investigation.

For serum products, the dosing interval is closely tied to the half‑life of the antibody. For example, therapeutic IgG preparations are typically given every 3–4 weeks, while monoclonal antibodies designed for extended half‑life may be dosed every 6–12 weeks. The goal is to maintain serum concentrations above the therapeutic threshold while minimizing peak‑to‑trough variability.

Therapeutic Uses/Clinical Applications

Vaccines

Approved indications for vaccines encompass a wide spectrum of infectious diseases, ranging from childhood immunizations to adult prophylaxis and outbreak control. Major vaccine series include:

• Measles, mumps, rubella (MMR)
• Polio (IPV & sIPV)
• Hepatitis B and A
• Influenza (inactivated, live attenuated, and recombinant)
• Human papillomavirus (HPV)
• COVID‑19 (mRNA, viral‑vector, and inactivated)
• Varicella, shingles (zoster)
• Typhoid, pertussis, diphtheria, tetanus (combined formulations)

Off‑label uses, while less common, are occasionally employed in specific clinical scenarios. For instance, tetanus immune globulin is used prophylactically in cases of contaminated wounds, and rabies immune globulin is administered post‑exposure in high‑risk contacts. Live attenuated vaccines are sometimes used in outbreak settings to provide rapid herd immunity, even in populations where routine vaccination coverage is low.

Sera (Antibody Preparations)

Indications for passive antibody therapy include:

• Rabies post‑exposure prophylaxis – rabies immune globulin in conjunction with rabies vaccine.
• Botulism antitoxin – equine or human polyclonal antitoxin for neutralization of botulinum toxin.
• Tetanus immune globulin – for wound prophylaxis in patients lacking prior immunity.
• Anti‑streptolysin O antitoxin – rarely used in severe streptococcal toxic shock syndrome.
• Human immunoglobulin preparations – used for passive protection against a variety of pathogens in immunocompromised patients (e.g., HIV‑positive individuals, patients undergoing chemotherapy).
• Monoclonal antibody therapies – e.g., palivizumab for RSV prophylaxis in preterm infants, and monoclonal antibodies targeting SARS‑CoV‑2 variants for high‑risk patients.

Emerging therapeutic antibodies targeting bacterial toxins (e.g., anti‑C. difficile toxins), viral antigens (e.g., anti‑influenza monoclonals), and cytokines (e.g., anti‑IL‑6 antagonists) are entering clinical practice, extending the scope of serum pharmacology beyond traditional indications.

Adverse Effects

Vaccines

Local reactions at the injection site are the most frequent adverse events. These may include pain, redness, swelling, and, rarely, induration. Systemic reactions can manifest as fever, malaise, and arthralgia, typically resolving within 48–72 hours. Serious adverse events are uncommon but may include anaphylaxis, Guillain-Barré syndrome (particularly associated with influenza vaccination), and immune‑mediated disorders such as autoimmune encephalitis. The incidence of such reactions is generally low, with risk estimates ranging from 1 in 100,000 to 1 in 1,000,000 doses, depending on the vaccine and population.

Adjuvant‑related reactogenicity is also a consideration. Aluminum‑based adjuvants can induce prolonged local inflammation, whereas oil emulsions may cause granulomatous reactions. The risk of vaccine‑associated adverse events is balanced by the high efficacy and public health benefits of vaccination programs.

Sera (Antibody Preparations)

Common side effects of antibody products include infusion or injection site reactions such as pain, erythema, and edema. Systemic reactions may involve fever, chills, headache, or hypotension, particularly with rapid IV infusion rates. Serious adverse reactions encompass anaphylaxis, serum sickness (immune complex deposition resulting in fever, rash, arthralgia, and renal impairment), and hemolytic anemia in the setting of anti‑erythrocyte antibodies.

Monoclonal antibodies can provoke infusion‑related reactions mediated by cytokine release, presenting as fever, rigors, or hypotension. These reactions are mitigated by premedication with antihistamines, acetaminophen, or corticosteroids, and by slowing infusion rates. The risk of serious hypersensitivity reactions remains low, yet vigilance is warranted, especially in patients with a history of prior hypersensitivity to biologic agents.

Drug Interactions

Vaccines

Vaccines are generally considered pharmacologically inert with respect to classic drug–drug interactions mediated by cytochrome P450 enzymes. However, certain concomitant medications can modulate vaccine efficacy. Immunosuppressive agents such as corticosteroids, methotrexate, or biologics (e.g., anti‑TNF agents) may blunt the immune response to vaccination, leading to reduced antibody titers. In such cases, timing of vaccine administration relative to immunosuppressive therapy may be optimized to enhance immunogenicity.

Live attenuated vaccines are contraindicated in patients receiving high‑dose systemic corticosteroids (>20 mg prednisone equivalent daily) or other potent immunosuppressants, due to the risk of vaccine‑associated disease. Live vaccines should also be avoided in patients with severe immunodeficiency, such as advanced HIV infection (CD4 <200 cells/µL).

Sera (Antibody Preparations)

Passive antibody therapies can interact with concomitant medications through competition for FcRn binding or by modulating immune complex clearance. For example, high‑dose intravenous immunoglobulin (IVIG) therapy can interfere with the pharmacokinetics of monoclonal antibodies by saturating FcRn, thereby accelerating their clearance. Conversely, IVIG may reduce the risk of hypogammaglobulinemia associated with certain chemotherapeutic regimens.

Antibody products are not metabolized by hepatic enzymes, so classic enzyme induction or inhibition interactions are unlikely. Nonetheless, the presence of circulating antigens may alter the serum concentration of therapeutic antibodies, a phenomenon termed target‑mediated drug disposition. In patients with high antigen loads (e.g., active infections), antibody clearance may increase, necessitating dose adjustments.

Special Considerations

Pregnancy and Lactation

Vaccination during pregnancy is recommended for certain vaccines to protect both the mother and the fetus. Inactivated vaccines (e.g., influenza, Tdap) are considered safe and are routinely administered during the third trimester. Live attenuated vaccines are contraindicated in pregnancy due to theoretical fetal risk. The timing of vaccination is important; for example, Tdap is most effective when given between 27 and 36 weeks of gestation, ensuring passive antibody transfer via the placenta.

Lactation is generally compatible with most vaccine administrations. Inactivated vaccines are considered safe during breastfeeding. Live attenuated vaccines may pose a theoretical risk of transmission via breast milk, though evidence is limited; therefore, clinicians often advise a brief cessation of breastfeeding following vaccination, particularly for highly immunogenic live vaccines.

Pediatric and Geriatric Considerations

Pediatric populations require age‑specific dosing schedules, as immune maturity and body composition differ from adults. Vaccine formulations may contain different antigen doses or adjuvants tailored to the pediatric immune response. The immunogenicity of certain vaccines may be attenuated in the elderly due to immunosenescence, necessitating higher antigen doses or the inclusion of adjuvants to elicit adequate protection.

Geriatric patients often present with comorbidities and polypharmacy, influencing vaccine scheduling and potential interactions. Vaccination strategies may prioritize high‑risk groups (e.g., influenza, pneumococcal) and consider the timing of immunosuppressive therapies to maximize efficacy.

Renal and Hepatic Impairment

Renal impairment does not significantly affect vaccine pharmacokinetics, as antigen clearance is primarily mediated by proteolytic degradation and immune processing. However, patients with end‑stage renal disease may exhibit altered immune responses; thus, vaccine efficacy may be diminished, warranting booster doses or alternative vaccination strategies.

Hepatic impairment can influence the metabolism of adjuvants and the synthesis of complement components critical for antibody function. In patients with cirrhosis, vaccine responses are often suboptimal, particularly for inactivated vaccines. Adjusting vaccine schedules and monitoring serologic responses can help optimize protection in this population.

Summary/Key Points

• Vaccines and sera represent biologic therapeutics that operate through distinct immunologic mechanisms, with vaccines inducing active immunity and sera providing passive protection.
• Classification of vaccines (live attenuated, inactivated, subunit, mRNA, viral‑vector) informs both pharmacodynamic properties and safety profiles.
• Pharmacokinetics of vaccine antigens involve rapid local uptake and processing by APCs, while antibody preparations exhibit extended half‑lives governed by FcRn recycling.
• Approved indications span a broad range of infectious diseases; off‑label uses are limited but clinically relevant in specific scenarios.
• Adverse reactions to vaccines are predominantly local and mild, with rare serious events; antibody products can cause infusion reactions and, rarely, serum sickness.
• Drug interactions with vaccines are largely immunomodulatory, whereas serum products may be affected by FcRn competition and target‑mediated disposition.
• Special patient groups require tailored vaccination strategies, considering pregnancy status, age, comorbidities, and organ function.
• Ongoing advances in vaccine technology (e.g., mRNA, viral‑vector) and antibody engineering (Fc modifications, bispecifics) promise enhanced efficacy and safety, underscoring the need for continual pharmacologic surveillance.

References

1. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
2. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
3. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
4. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
5. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
6. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
7. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
8. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.